UNC researchers report a new way to charge CAR-T against solid tumors
When researchers first started putting CAR-T cells into cancer patients in the 1990s, the cells didn’t do very much. They swam around in the blood, killing very little of what they were meant to kill, before dying a quiet death some months later.
There were several big reasons for the failures. Researchers at first picked the wrong diseases, going after solid tumors that, it turned out, were uniquely adept at keeping out T cells. And they didn’t even really know which parts of these tumors were the best to aim at.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.